社区获得性肺炎的诊断和治疗进展

被引:30
作者
龙威
黄高忠
机构
[1] 上海交通大学附属上海市第六人民医院老年病科
关键词
D O I
暂无
中图分类号
R563.1 [肺炎];
学科分类号
100201 [内科学];
摘要
<正>社区获得性肺炎(communityacquired pneumonia,CAP)是指医院外罹患的感染性肺实质炎症,是威胁人类健康的主要疾病之一,在世界范围内具有高发病率和长期潜在死亡率,给社会带来巨大的经济负担[1-3]。CAP同样是老年人的常见病,在美国列住院病因第2位,列死因第4位,老年CAP的发病率、死亡率较年轻人明显增加,>65岁人群死亡率可≥10%[4]。世界各国相关权威机构为了提高CAP的诊治水平,改善患者的预后,纷纷出台CAP的诊治指南,并不断修订[4-5]。每年均有关于CAP方面的研究发布,本文对此做一综述。
引用
收藏
页码:73 / 76
页数:4
相关论文
共 12 条
[1]
老年肺炎患者并发心律失常的危险因素分析 [J].
杨波 ;
姜宏宁 ;
余敏 ;
张慧荣 ;
龙霖梓 .
实用老年医学, 2014, 28 (05) :377-379
[2]
电解质紊乱对老年重症肺炎患者预后的影响 [J].
姚鸣华 .
实用老年医学, 2014, 28 (04) :294-295+298
[3]
Community-acquired pneumonia [J].
Remington, Leah T. ;
Sligl, Wendy I. .
CURRENT OPINION IN PULMONARY MEDICINE, 2014, 20 (03) :215-224
[4]
The Hospitalist Perspective on Treatment of Community–Acquired Bacterial Pneumonia.[J].Amin;Cerceo;Deitelzweig;Pile;Rosenberg;Sherman.Postgraduate Medicine.2014, 2
[5]
Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia [J].
Adamuz, Jordi ;
Viasus, Diego ;
Jimenez-Martinez, Emilio ;
Isla, Pilar ;
Garcia-Vidal, Carolina ;
Dorca, Jordi ;
Carratala, Jordi .
JOURNAL OF INFECTION, 2014, 68 (06) :534-541
[6]
Severe sepsis and septic shock.[J].Christa A Schorr;Sergio Zanotti;R Phillip Dellinger.Virulence.2014, 1
[7]
Current treatment of community-acquired pneumonia [J].
Liapikou, Adamantia ;
Torres, Antonio .
EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (10) :1319-1332
[8]
Community-Acquired Pneumonia: Symptoms and Burden of Illness at Diagnosis among US Adults Aged 50 Years and Older [J].
Wyrwich, Kathleen W. ;
Yu, Holly ;
Sato, Reiko ;
Strutton, David ;
Powers, John H. .
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2013, 6 (02) :125-134
[9]
Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay; total hospital charges; and mortality.[J].Gerry Oster;Ariel Berger;John Edelsberg;David J. Weber.Journal of Medical Economics.2013, 6
[10]
Synthesis and antibacterial evaluation of novel 11;4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria.[J].Xin Li;Siti Ma;Mi Yan;Yuanze Wang;Shutao Ma.European Journal of Medicinal Chemistry.2013,